Premium
Cardiotrophin‐1 (CT‐1): a novel hypertrophic and cardioprotective agent
Author(s) -
Latchman David S.
Publication year - 1999
Publication title -
international journal of experimental pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.671
H-Index - 72
eISSN - 1365-2613
pISSN - 0959-9673
DOI - 10.1046/j.1365-2613.1999.00114.x
Subject(s) - in vivo , medicine , cardiac hypertrophy , muscle hypertrophy , myocyte , in vitro , cardiac myocyte , stat , signal transduction , pharmacology , cardiology , microbiology and biotechnology , endocrinology , chemistry , biology , stat3 , biochemistry
Cardiotrophin‐1 (CT‐1) is a member of the IL‐6 family of cytokines which was originally discovered as a factor which can induce hypertrophy of cardiac myocytes both in vitro and in vivo . Subsequently, CT‐1 has been shown to have a wide variety of different effects on cardiac and non cardiac cells including the ability to stimulate the survival of both cardiac and neuronal cells. Interestingly, whilst activation of the p42/p44 MAP kinase pathway is necessary for the survival promoting effects of CT‐1 in cardiac cells, it is not required for its hypertrophic effect which is likely to involve activation of the Jak/STAT‐3 pathway. CT‐1 may therefore be of use as a novel cardio‐protective agent, particularly if its hypertrophic effect can be specifically inhibited.